ESSA Pharma Inc. Class Action: The Gross Law Firm Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX

1. Class action lawsuit for EPIX shareholders from Dec 2023 to Oct 2024. 2. Allegations include misleading efficacy statements about prostate cancer treatment. 3. Study data suggests masofaniten's ineffectiveness compared to enzalutamide. 4. Defendants accused of overstating commercial prospects of their treatment. 5. Deadlines for shareholders to participate are set for March 25, 2025.

Legal

95

4m saved

Insight

Article

FAQ

Why Very Bearish?

The allegations against EPIX suggest significant misinformation regarding clinical efficacy, damaging investor trust. Historical precedents show that similar cases have led to drastic stock price declines for involved companies.

How important is it?

The lawsuit addresses severe allegations of misleading statements that directly affect EPIX's credibility and market position. Due to the potential financial ramifications and investor sentiment, it is highly consequential.

Why Short Term?

The immediate reaction from investors is likely due to the lawsuit announcement. Stock prices may decline until further clarity on legal proceedings is provided.

Related Companies

EPIX PFE JNJ

NEW YORK, March 6, 2025 /PRNewswire/ - The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX).

Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE: https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=134039&from=4

CLASS PERIOD: December 12, 2023 to October 31, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (ii) the M-E Combination Study, a monotherapy and combination therapy for the treatment of prostate cancer, was unlikely to meet its prespecified Phase 2 primary endpoint; (iv) accordingly, defendants had overstated masofaniten's clinical, regulatory, and commercial prospects; and (v) as a result, defendants' public statements were materially false and misleading at all relevant times.

DEADLINE: March 25, 2025. Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=134039&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of EPIX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 25, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: The Gross Law Firm, 15 West 38th Street, 12th floor, New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903

SOURCE The Gross Law Firm